Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan," said Dr. John Moller, CEO of Novotech. "This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
BOSTON -- Businesswire -- Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech’s extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech’s project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company’s ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Novotech
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 서울 평창동 이엔갤러리, 남재현 작가 ‘Moon Over September’ 개인전 개최 - 뉴스와이어
- 항공안전기술원, 드론 실증도시 구축사업으로 지자체별 지역 특성 맞춤형 드론 활용 서비스 지
- 두구다, 중기부 ‘팁스’ 선정… AI 기반 의료 경영 최적화 솔루션 ‘메디버니’ 개발 본격화 -
- GC녹십자, 혈우병 환자 개인맞춤형 소프트웨어 ‘WAPPS-HEMO’ 업그레이드 출시 - 뉴스와이어
- 인천창조경제혁신센터-대한항공, 항공우주산업 분야 오픈이노베이션 사업설명회 개최 - 뉴스와
- 가을 밤을 사로잡은 ‘제3회 논산 월드 뮤직페스티벌’ - 뉴스와이어
- 한국지역난방공사, 2024년도 신입직원 68명 임용 - 뉴스와이어
- SAS코리아, 이중혁 신임 대표이사 선임 - 뉴스와이어
- 대웅제약, 숙취해소제 ‘에너씨슬 퍼펙트샷 쎈’ 출시 - 뉴스와이어
- 미타운, 스냅박스AI와 전략적 파트너십 MOU 체결 - 뉴스와이어